3-yl)-2-(fluoromethoxyimino)acetamido]
-3-[(£' )-2-((5)-2,2-dimethyl-5-isoxazolidinio)vinyl]-3-cephem-4-carboxylate (YM-40220), which showed well-balanced in vitro activity and an excellent in vivo efficacy against Staphylococcus aureus Smith, as a candidate for further development.
In our preceding paperij, we reported a cephem 1 (YM-32825) bearing a (dimethylisoxazolidinio)vinyl substituent at its 3-position ( Fig. 1 ) which showed good in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, except Enterococcus faecalis and Pseudomonasaeruginosa, and excellent in vivo efficacy against Staphylococcus aureus. In our continuous efforts to prepare highly potent cephalosporins which retain strong in vivo activity against S. aureus and possess a favorable broader spectrum of activity, we attempted the structural modifications of 1 (Scheme 1). Thus, the C-7 substituents as well as the olefin geometry of the C-3 side chain (i.e., (E) or (Z)) were altered. Here we wish to report the structure-activity relationships of those compounds. Also the stereochemistry of an isoxazolidine ring was investigated regarding themost potent compound,2d-II (YM-40220). Chemistry Preparationof the 7-acyl variants (2a, b', c~e) is portrayed in Scheme 2. Thesecompoundswere synthesized usingthecorrespondingcarboxylic acids (3a~e) by a method similar to that described for 11}. Acids3a~e were coupled with /?-methoxybenzyl 7-amino-3-chloromethylcephalosporinate viaacyl chloride. The resulting 5a~e were converted to alcohols6a~e underPd(0)-catalyzed cross-coupling conditions2). Eliminationwas achieved by conversionof thehydoxy groupinto phosphate and subsequenttreatment with diisopropylethylamine. Cycloadditionof a nitrone with 7-acylamino-3-(l,3-butadienyl)cephems (8a~e) proceeded regiospeci- Scheme 2. Synthesis of cephalosporins from 3-chloromethyl derivatives (5a~5e).
Scheme 3. Synthesis of cephalosporins from a 3-triflate (ll).
fically. After quaternization by methyl iodide, trityl (Tr) An alternative approach from commercially available and /?-methoxybenzyl (PMB) groups were removed using /?-methoxybenzyl 3-hydroxy-7-phenylacetylcephalospor-TFA/H2Oand TFA/anisole systems. Each diastereomer inate is depicted in Scheme 3. The 3-hydroxy cephem was separated by preparative HPLC:More polar, (2a, was converted to the known triflate 113), which was b', c, d and e)-I; less polar, (2a, b', c, d and e)-II. subjected to Pd(O)-catalyzed coupling reaction with tributyl(l,3-butadienyl) 23. To avoid epimerization during the deprotection process, 23 was reacylated to 24 with 2~(5-arninoA,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetic acid by the HOBT-DCC method. Compound24 was quaternized and the PMBgroup was removed using TFA/ anisole below 0°C. HPLCanalysis revealed that the crude product consisted of 2d-I and 2d-II in a ratio of 9 : 1. Thus, the absolute configuration of 2&-I was (R) and therefore that of 2d-II was (S).
Antibacterial Activity The in vitro activity of the new cephalosporins ((2a9 b', c, d, e)-I, -II and 2f) against selected Gram-positive and Gram-negative bacteria are summarized in Table 1 . For comparison, the MIC values for cefpirome (CPR), ceftazidime (CAZ), flomoxef (FMOX) and 1 (YM-32825) are also listed. MICswere determined by the standard 2-fold serial agar dilution method in Mueller-Hinton Table 1 . Comparative activity (MIC, //g/ml) of 3-(2,2-dimethyl-5-isoxazolidinio)vinylcephem compounds. Comparing the two geometric isomers (21-1 or -II vs. 1), the (Z)-isomer was less potent than the (ii)-isomer against both Gram-positive and Gram-negative bacteria.
Improvement of the anti-pseudomonal activity was accomplished by replacing a 2-aminothiazolyl moiety with a 5-amino-l,2,4-thiadiazolyl moiety (2c-I or -II vs. 1, and 2d-I or -II vs. 2a-I or -II). Especially, 2d-I exhibited somewhat higher anti-pseudomonal activity than that of CAZ. In the 5-amino-1,2,4-thiadiazolyl series, substitutions with methoxy, fluoromethoxy and fluoroethoxy groups showed favorable activity. Among them, a fluoromethoxyiminocephem displayed the most wellbalanced spectrum activity over a wide range of Grampositive and Gram-negative bacteria. The hydroxyimino cephem (2f) was the most potent against Gram-positive bacteria including E. faecalis among the compounds tested. However, its activity against Gram-negative bacteria was modest.
The in vivo efficacy of 2d-I and 2d-II against systemic infections by S. aureus Smith is shown in Table 2 From the data mentioned above, we selected 2d-II (YM-40220), which has an (S) configuration at the 5-position of an isoxazoline ring, as a candidate for further development. MICs were determined by the 2-fold serial agar dilution method using Mueller-Hinton agar (pH 7.2) after incubation at 37°C for 18 hours with an inoculum size of 106 cfu/ml. For experimental Staphylococcal infection, septicemia was induced in male Crj: CD-I mice (4 to 5 weeks old, n=6). Mice were intraperitoneally infected with a single 0.5 ml inoculum containing a lethal dose of S. aureus Smith (3.3x 106cfu/mouse). Test compoundswere administered subcutaneously two hours after the bacterial challenge. The effective dose (ED50, mg/kg) was calculated based on probit analysis from survival rates 7 days after infection.
Synthesis of the Compounds
Regarding the synthesis depicted in Scheme 2, the typical procedures for 6d, 7d, 8d, 9d and lOd are presented. Other compounds, (6, 7, 8, 9 , 10)-a, -b, -c and -e, were prepared similarly. Yields, typical XHNMR chemical shifts, IR and mass data of these compounds are summarized in Table 3 . KBr, cm"1. bm/z; (M+H)+ for (6, 7, 8, 9)-a, -b, -c, -e and 15. (M-I)+ for 10-a, -b, -c and 16.
A solution of 6d (6.63g, 7.94mmol) and DMAP (1.455g, ll.9mmol) in CH2C12 (130ml) was treated dropwise with diphenyl chlorophosphate (2.48 ml, 1 1.9 mmol) at -50°C. The cooling bath was removed and the reaction was allowed to proceed at 25°C for 1 hour. The reaction mixture was partitioned between ice-water/ CH2C12.The aqueous phase was further extracted with CH2C12. The combined organic phase was dried over MgSO4and concentrated. The residue was purified by silica gel chromatography with w-hexane -AcOEt (1 50 ml) was treated with diisopropylethylamine (3.8 ml, 22mmol)at 0°C. The reaction was allowed to proceed at 25°C overnight. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with CHC13to afford 8d 
A solution of 9d (438mg, 0.5mmol) was treated with methyl iodide (355 mg, 2.5 mmol). After the solution was stirred overnight at room temperature, the volatiles were removed at the pump. The residue was triturated with Et2O 
A DMFsolution oflOd (5.25 g, 5.16mmol) and anisole (63ml) in CH2C12 (100ml) was treated with TFA (160ml). After stirring for 1 hour at room temperature, the mixture was concentrated under reduced pressure, and the residue was triturated with Et2O. The collected solid was dissolved in TFA (150ml) and water (150ml) NOV. 1996 was added with an ice-bath cooling. (13) To a suspension of PC15 (10g, 48mmol) in CH2C12 (170ml) pyridine (3.88ml, 48mmol) was added at 4°C, and the mixture was stirred for 1 hour. A butadienyl cephem 12 (7.81g, 15.9mmol) was then added by portions and stirring was continued for a further 1.5
hours at 4°C. The mixture was cooled to -72°C and treated dropwise with MeOH(64ml). The reaction was allowed to proceed for an additional 1 hour, during which time the temperature was raised to -25°C. The mixture was poured into water (300ml) and extracted with CH2C12.The combined extracts were washed with water and brine, dried over MgSO4,and concentrated in vacuo. The residual oil was washed well with n-pentane and triturated with AcOEt-Et2O (1 : 1) to afford 13 To a suspension of 13 (1.03g, 4.95mmol) in CH2C12 (20ml) was added 7V,O-bis(trimethylsilyl)acetamide (BSA) (1.12ml), and the mixture was stirred at room temperature for 85 minutes. The resulting solution was cooled to -40°C and pyridine (1.6ml, 20mmol) was added. A solution of (Z)-2-(5-ter/-butoxycarbonylamino-1 ,2,4-thiadiazol-3-yl)-2-(1-methoxy-1-methylethoxyimino)acetyl chloride, prepared from the corresponding acid6) (1.72g, 4.73mmol) and PC15 (1.03g, 4.95mmol) at -25°C, was subsequently added. After stirring at -40°C to -25°C for 1.5 hours, the mixture was poured into sat. NaH2PO4 (100ml).
The water phase was extracted with GHC13(100ml x 2). The combined organic fractions were dried over MgSO4and concentrated. The crude product was purified by column chromatography on silica gel with AcOEt-w-hexane 
A methylene chloride solution of compound 16
(251 mg, 0.27 mmol) and anisole (0.2ml) was treated with TFAat roomtemperature for 2 hours. The mixture was concentrated under reduced pressure and triturated with Et2O to afford the crude solid. The sjw-isomer 2f (35 mg, 26%) was obtained by preparative HPLC (5% CH3CN-0.01 m aq. KH2PO4) as described for 2d-I. Physical data are shown in Table 4 . To a mixture ofacrolein (1.1 ml, 16.5mmol), 38% aq. HCHO (2.65 ml, 33 mmol) and AcONa (2.06g, 25 mmol) in dioxane (150ml) was added a solution of iV-methylhydroxylamine hydrochloride (2.10 g, 25 mmol) in 80% aq. EtOH(33.5ml). The reaction mixture was heated under reflux for 3 hours. The mixture was then cooled to roomtemperature and concentrated under reduced pressure. EtOH (50ml) was added and insoluble materials were filtered off. EtOHwas removed by evaporation to obtain the crude aldehyde (4.12g), which was used without further purification. 
Compound 19 (227 mg, 0.265 mmol) was transformed to a quarternary ammonio cephem 20, which was deprotected in a fashion similar to that described for 2d-I. Preparative HPLC was performed with 7.5% CH3CN-0.01 m aq. KH2PO4. Desalting and lyophilization gave 21-1 (llmg, 9%) amd 21-ll (16mg, 12%).
Physical data are shown in Table 4 .
Compound 12 (8.9g, 8.14mmol ) was subjected to a 1,3-dipolar cycloaddition as described for 9d. After workup, the crude product was purified by silica gel column chromatography with CHCl3 -AcOEt (1 : 0-5: 1-3: 1) to yield 7.36g of 3-(isoxazolin-5-yl)vinylcephem. In this case, some (ca. 16%) isomerization of a double bond (J3->zt2) occurred concomitantly. The A2 isomer was removed by trituration with AcOEt. The pure A3 isomer (3.5g) was recrystallized from CHC13-MeOHtwice to yield a solid (640 mg), which was analyzed to be a 9 : 1 mixture of the (R)-and (S)-diastereomers by HPLC using a chiral column (Chiralcel AS (45) 
A mixture of PC15 (625mg, 3mmol) and pyridine (0.24ml, 3mmol ) was stirred at 0°C for 1 hour. The mixture was cooled to -20°C and 7-acylaminocephem (22:22'=9: 1, 550mg, 1 mmol) was added slowly. Stir- NOV. 1996 ring was continued for an additional 1 hour below 0°C. The resulting pale yellow solution was cooled to -70GC, and MeOH(4ml) was added dropwise. The temperature was raised to -15°C in 1.5 hours and water (15ml) was added. The mixture was partitioned between CH2C12/ H2Oand the aqueous layer was madebasic with Na2CO3 to pH 9 and extracted with AcOEt. The organic extracts were combined, washed with brine and dried over To a solution of 2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetic acid (178 mg, 0.81 mmol) in DMF (2ml) was added DCC (184mg, 0.89mmol) and HOBT(120mg, 0.89 mmol). After stirring for 15 minutes at roomtemperature, the mixture wasadded to a solution of 23 (340mg, 0.79mmol) in DMF(3 ml). The resulting mixture was stirred at room temperature for 14.5 hours. Insoluble materials were filtered off, and the filtrate was concentrated under reduced pressure. The residue was partitioned between AcOEt / H2O. The organic layer was washed with brine, dried over MgSO4and evaporated.
The crude product was purified by silica gel column chromatography with revealed that the product consisted of 2d-I and 2d-II in the ratio of9: 1.
